1.5 mg/m2 intravenous (IV) bolus push over 3 to 5 seconds on days 1, 4, 8, and 11, followed by a 10-day rest for a 21-day cycle.

Other Names:

Velcade

LPD-341

MLN341

PS-341

Experimental: Arm B (other B-cell lymphomas)

Drug: PS341 (Bortezomib)

1.5 mg/m2 intravenous (IV) bolus push over 3 to 5 seconds on days 1, 4, 8, and 11, followed by a 10-day rest for a 21-day cycle.

Other Names:

Velcade

LPD-341

MLN341

PS-341

Detailed Description:

Patients were stratified, based on preclinical data, into arm A (mantle-cell lymphoma) or arm B (other B-cell lymphomas) without limitation in number of prior therapies. Bortezomib was administered as an intravenous push (1.5 mg/m2) on days 1, 4, 8, and 11 every 21 days for a maximum of six cycles.

No serious intercurrent illness, active infections or cancer except basal cell carcinoma of the skin or in situ cervical carcinoma.

Not eligible for treatment of a higher priority. Patients may be entered before BMT.

No pregnancy & age bearing females must be practicing adequate contraception.

Age > 16.

EXCLUSION:

Patients with platelets <30x10(9)/L within 14 days before enrollment.

Patients with ANC<1.0 x10(9)/L within 14 days before enrollment.

Patients with peripheral neuropathy >/= grade 3 within 14 days before enrollment.

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00038571